Study Evaluating Isovorin in Colon Cancer

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: September 12, 2005
Last updated: August 12, 2009
Last verified: August 2009

The purpose of the study is to verify superiority of 1-LV/5FU therapy to UFT Therapy of relapse-free survival time in patients with Dukes C and Cure A colon cancer. Secondary endpoints include disease-free survival time, survival time, and safety.

Condition Intervention Phase
Colon Cancer
Drug: Isovorin
Drug: UFT
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Post-Approved Phase III Study of 1-LV/5FU Therapy

Resource links provided by NLM:

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Relapse-free survival time

Secondary Outcome Measures:
  • Disease-free survival time, survival time, safety

Estimated Enrollment: 650
Study Start Date: October 2002
Study Completion Date: February 2006
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   20 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Dukes C, Cure A colon cancer diagnosed histologically or cytologically
  • Normal organ function of bone marrow, heart, liver and kidney
  • Age 20-75

Other inclusion applies

Exclusion Criteria:

  • Serious bone marrow suppression, infection, heart disease or complication
  • Familial adenomatous polyposis or hereditary nonpolyposis
  • Pregnant or breastfeeding women

Other exclusion applies

  Contacts and Locations
Please refer to this study by its identifier: NCT00195585

Tokyo, Japan, 104-0031
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided Identifier: NCT00195585     History of Changes
Other Study ID Numbers: ISO/5FU-11
Study First Received: September 12, 2005
Last Updated: August 12, 2009
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Colon Cancer

Additional relevant MeSH terms:
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Protective Agents processed this record on April 17, 2014